Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $3.5 million.

  • Tonix Pharmaceuticals Holding's Receivables - Net fell 1325.69% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1325.69%. This contributed to the annual value of $3.7 million for FY2024, which is 1976.03% down from last year.
  • Tonix Pharmaceuticals Holding's Receivables - Net amounted to $3.5 million in Q3 2025, which was down 1325.69% from $2.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Receivables - Net's 5-year high stood at $4.6 million during Q4 2023, with a 5-year trough of $1.6 million in Q3 2023.
  • Its 3-year average for Receivables - Net is $3.3 million, with a median of $3.4 million in 2024.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Receivables - Net soared by 15691.42% in 2024, and later tumbled by 3051.81% in 2025.
  • Tonix Pharmaceuticals Holding's Receivables - Net (Quarter) stood at $4.6 million in 2023, then dropped by 19.76% to $3.7 million in 2024, then fell by 5.48% to $3.5 million in 2025.
  • Its Receivables - Net was $3.5 million in Q3 2025, compared to $2.3 million in Q2 2025 and $3.3 million in Q1 2025.